Targeted Oncology
Targeted Oncology
Targeted Oncology

Specialties

Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Charles M. Rudin, MD, PhD, chief, thoracic oncology, Memorial Sloan Kettering Cancer, discusses a study of intravenously delivered coxsackievirus A21 with pembrolizumab to treat patients with advanced cancers.
Ceritinib Approved by the FDA for Frontline ALK+ NSCLC
Ceritinib (Zykadia) has been approved by the FDA for the treatment of patients with ALK-positive, metastatic non–small cell lung cancer.
KTE-C19 Granted Priority Review by FDA for Non-Hodgkin Lymphoma
Axicabtagene ciloleucel (KTE-C19; axi-cel) has been granted a priority review by the FDA for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.
Nivolumab Granted FDA's Priority Review for Liver Cancer
Nivolumab (Opdivo) has been granted a priority review designation by the FDA for use as a treatment for patients with hepatocellular carcinoma following prior sorafenib (Nexavar).
Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers. 
Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses a study of the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors in mantle cell lymphoma (MCL).
View More >

Features

Frontline Pembrolizumab Combo Approved by FDA for NSCLC
Frontline Pembrolizumab Combo Approved by FDA for NSCLC
Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non-small cell lung cancer.
Copanlisib Granted Priority Review Designation by FDA for Follicular Lymphoma
Copanlisib has been granted a priority review designation by the FDA as a treatment for patients with relapsed/refractory follicular lymphoma who have received at 2 least prior therapies.
Avelumab Approved by FDA for Bladder Cancer
The FDA has granted an accelerated approval to the PD-L1 inhibitor avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Entrectinib Granted Breakthrough Designation by FDA for NTRK+ Solid Tumors
Entrectinib has been granted breakthrough therapy designation by the FDA for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors.
Brigatinib Approved by FDA for ALK-Positive NSCLC
Brigatinib (Alunbrig) has been granted an accelerated approval by the FDA as a treatment for patients with metastatic ALK-positive non-small cell lung cancer who are resistant to prior crizotinib.
Publications